You are here

FDA Approves Fine-Particle Diclofenac (Zorvolex) for Acute Pain

Dosing strength is lower than that of other diclofenac products (October 21)

The FDA has approved Zorvolex (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild-to-moderate acute pain in adults. The drug was approved at dosage strengths that are 20% lower than those of currently available diclofenac products.

The agency’s approval was based on data from a phase III randomized study in which patients treated with Zorvolex reported significant pain relief compared with those receiving placebo.

Zorvolex consists of diclofenac as submicron particles that are approximately 20 times smaller than their original size. The reduction in particle size provides an increased surface area, leading to faster dissolution, according to the product’s developer (Iroko Pharmaceuticals).

Zorvolex was developed to address the FDA’s public health advisory recommending that NSAIDs be used at the lowest effective dose for the shortest period consistent with the individual patient’s treatment goals. The risk of serious adverse events, including cardiovascular thrombotic events, myocardial infarction, stroke, gastrointestinal (GI) ulcers, GI bleeds, and renal events, such as acute renal failure, associated with NSAIDs is greater among patients receiving higher doses.

Source: Iroko Pharmaceuticals; October 21, 2013.

Recent Headlines

Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs